Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL740860

CCc1ccc(OC)c(S(=O)(=O)n2cc3c4c(cccc42)CNCC3)c1.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.38
HTR2C P28335 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.35
HMOX1 P09601 1/20 0.35
KDM1A O60341 1/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 3/20 0.34
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
RXFP1 Q9HBX9 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL743820 0.93 HTR6 (0.43) HTR6HTR2CSMN1; SMN2HMOX1KMT2A
Trifluoroacetic Acid SCHEMBL742728 0.89 HSD17B10 (0.41) HTR6HTR2CSMN1; SMN2KMT2APOLB
Trifluoroacetic Acid SCHEMBL741228 0.84 HTR6 (0.40) HTR6HTR2CSMN1; SMN2POLBALDH1A1
Trifluoroacetic Acid SCHEMBL739965 0.82 KMT2A (0.43) HTR6SMN1; SMN2KMT2AALDH1A1LMNA
Trifluoroacetic Acid SCHEMBL741805 0.81 HTR6 (0.38) HTR6HTR2CPKM
SCHEMBL742328 0.81 KMT2A (0.46) HTR6HTR2CKMT2AALDH1A1LMNA
Trifluoroacetic Acid SCHEMBL740867 0.80 HTR6 (0.39) HTR6HTR2C
Trifluoroacetic Acid SCHEMBL743618 0.80 HTR6 (0.49) HTR6HTR2CKDM1AALDH1A1LMNA
Trifluoroacetic Acid SCHEMBL742666 0.79 HTR6 (0.47) HTR6HTR2C
Trifluoroacetic Acid SCHEMBL743935 0.79 HTR6 (0.40) HTR6HTR2CSMN1; SMN2KDM1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138333-B2 Sulfonyl-indole derivatives PROXIMAGEN LIMITED (GB) 2012-03-20 US disclosed
EP-2134714-A1 TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY Biovitrum AB (publ) (SE) 2009-12-23 EP disclosed
US-20080293694-A1 New compounds BIOVITRUM AB (PUBL.) (SE) 2008-11-27 US disclosed
WO-2008110598-A1 TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY BIOVITRUM AB (PUBL) (SE) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293694-A1 New compounds HTR6, HTR1A, HTR1B HTR6 1/4885HTR2C 8/4885SMN1; SMN2 1945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.